GLP-1 Medications and Immigration Medical Exams: What You Need to Know
How GLP-1 weight loss medications affect immigration medical exams, green card physicals, and health-related visa requirements.
More on Healthcare Requirements
Key Takeaway
GLP-1 medications do not negatively affect immigration medical exams. Obesity is not a ground of inadmissibility. Managing health conditions with GLP-1 medications demonstrates responsible healthcare and supports a favorable medical evaluation.
Immigration Medical Exams and Health
The I-693 immigration medical examination, performed by USCIS-designated civil surgeons, evaluates applicants for certain health-related grounds of inadmissibility. While obesity itself is not disqualifying, managing associated conditions like diabetes, hypertension, and metabolic syndrome demonstrates proactive health management. Semaglutide and tirzepatide can help applicants present their best health profile.
What the Medical Exam Evaluates
The I-693 screens for Class A conditions (communicable diseases like TB, mental disorders with harmful behavior, substance abuse) and Class B conditions (conditions that may affect the applicant but are not disqualifying). Well-managed chronic conditions with appropriate medication are not barriers to approval.
Benefits of GLP-1 for Immigration Health
Improved blood pressure, blood sugar control, and overall metabolic health support a clean medical evaluation. Having an active treatment plan with regular medical care demonstrates health responsibility, which civil surgeons note favorably.
Practical Considerations
Tips for Your Medical Exam
- Bring a list of all current medications including GLP-1
- Bring recent lab results showing controlled conditions
- Have your prescribing doctor's contact information available
- Ensure vaccinations are up to date
Important Notes
- Never withhold medication information from civil surgeons
- GLP-1 prescriptions require legal U.S. prescription
- Immigration law is complex; consult an attorney for specific concerns
- I-693 is valid for 2 years from the civil surgeon's signature
Medical Disclaimer: This content is for informational purposes only. Consult an immigration attorney and healthcare provider for personalized guidance. Immigration policies may change; verify current requirements with USCIS.
Frequently Asked Questions
Does obesity affect immigration medical exam results?
Obesity itself is not a ground of inadmissibility. However, obesity-related conditions like uncontrolled diabetes, untreated hypertension, or severe sleep apnea could raise concerns during the I-693 medical examination. GLP-1 medications help manage these conditions proactively.
Should I disclose GLP-1 medication use on Form I-693?
Yes, you must disclose all current medications during your immigration medical exam. GLP-1 medications are FDA-approved prescription drugs and their use is not a negative factor. In fact, they demonstrate proactive health management.
Can I continue GLP-1 medications during the immigration process?
Yes. There is no restriction on using GLP-1 medications during immigration proceedings. Maintaining consistent medical care actually supports a favorable medical examination outcome by keeping health conditions well-managed.
Will my weight affect my immigration application?
Weight alone does not affect immigration eligibility. The medical exam evaluates for communicable diseases, mental health conditions, substance abuse, and vaccination requirements. GLP-1 medications address underlying metabolic health, which is always beneficial.
Affordable GLP-1 Treatment
Compounded semaglutide from $99/mo or tirzepatide from $125/mo. No insurance needed.
View Treatment OptionsSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).